Literature DB >> 18056388

Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs.

Anthony A Ryan1, Teresa M Wozniak, Elena Shklovskaya, Michael A O'Donnell, Barbara Fazekas de St Groth, Warwick J Britton, James A Triccas.   

Abstract

Modulating the host-immune response by the use of recombinant vaccines is a potential strategy to improve protection against microbial pathogens. In this study, we sought to determine whether secretion of murine GM-CSF by the bacillus Calmette-Guérin (BCG) vaccine influenced protective immunity against Mycobacterium tuberculosis. BCG-derived GM-CSF stimulated the in vitro generation of functional APCs from murine bone marrow precursors, as demonstrated by the infection-induced secretion of IL-12 by differentiated APCs, and the ability of these cells to present Ag to mycobacterium-specific T cells. Mice vaccinated with BCG secreting [corrected] murine GM-CSF (BCG:GM-CSF) showed increased numbers of CD11c+MHCII+ and CD11c-CD11b+F480+ cells compared with those vaccinated with control BCG, and this effect was most apparent in the draining lymph nodes at 7 and 14 days postvaccination. Vaccination with BCG:GM-CSF also resulted in enhanced expression of costimulatory molecules on migratory dendritic cells in the draining lymph nodes. The increased APC number was associated with an increase in the frequency of anti-mycobacterial IFN-gamma-secreting T cells generated after BCG:GM-CSF vaccination compared with vaccination with control BCG, and this effect was sustained up to 17 wk in the spleens of immunized mice. Vaccination with BCG:GM-CSF resulted in an approximately 10-fold increase in protection against disseminated M. tuberculosis infection compared with control BCG. This study demonstrates the potential of BCG secreting [corrected] immunostimulatory molecules as vaccines to protect against tuberculosis and suggests BCG:GM-CSF merits further appraisal as a candidate to control M. tuberculosis infection in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056388     DOI: 10.4049/jimmunol.179.12.8418

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Recombinant BCG as a vaccine vehicle to protect against tuberculosis.

Authors:  James A Triccas
Journal:  Bioeng Bugs       Date:  2009-11-02

2.  Keratinocyte growth factor administration attenuates murine pulmonary mycobacterium tuberculosis infection through granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent macrophage activation and phagolysosome fusion.

Authors:  Rajamouli Pasula; Abul K Azad; Jason C Gardner; Larry S Schlesinger; Francis X McCormack
Journal:  J Biol Chem       Date:  2015-01-20       Impact factor: 5.157

Review 3.  The role of dendritic cells in mycobacterium-induced granulomas.

Authors:  Heidi A Schreiber; Matyas Sandor
Journal:  Immunol Lett       Date:  2010-01-04       Impact factor: 3.685

4.  Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis.

Authors:  A Francisco-Cruz; D Mata-Espinosa; S Estrada-Parra; Z Xing; R Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 5.  T cells in mycobacterial infection and disease.

Authors:  Andrea M Cooper
Journal:  Curr Opin Immunol       Date:  2009-07-29       Impact factor: 7.486

Review 6.  Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.

Authors:  Alejandro Francisco-Cruz; Miguel Aguilar-Santelises; Octavio Ramos-Espinosa; Dulce Mata-Espinosa; Brenda Marquina-Castillo; Jorge Barrios-Payan; Rogelio Hernandez-Pando
Journal:  Med Oncol       Date:  2013-11-22       Impact factor: 3.064

Review 7.  Targeting the C-type lectins-mediated host-pathogen interactions with dextran.

Authors:  Sergey Pustylnikov; Divya Sagar; Pooja Jain; Zafar K Khan
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

Review 8.  Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Authors:  Yi Luo; Jonathan Henning; Michael A O'Donnell
Journal:  Clin Dev Immunol       Date:  2011-09-15

9.  Complex cytokine profiles induced by BCG vaccination in UK infants.

Authors:  Maeve K Lalor; Steven G Smith; Sian Floyd; Patricia Gorak-Stolinska; Rosemary E Weir; Rose Blitz; Keith Branson; Paul E Fine; Hazel M Dockrell
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

10.  Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.

Authors:  Wu Li; Guangcun Deng; Min Li; Xiaoming Liu; Yujiong Wang
Journal:  Tuberc Res Treat       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.